Monographie de FOQUEST®. Elvium Life Sciences. 23 avril 2024.
CADDRA - Canadian ADHD Resource Alliance. Lignes directrices canadiennes sur le TDAH, 4.1 édition. Toronto (Ontario); CADDRA, 2020.
Weiss MD et coll. Efficacy and safety of a long-acting multilayer-release methylphenidate formulation (PRC-063) in the treatment of adolescent Attention-Deficit/Hyperactivity Disorder: a randomized, double-blind clinical trial with a 6-Month open-label extension. J Child Adolesc Psychopharmacol 2021;31(9):610-622.
Weiss MD et coll. Efficacy and safety of PRC-063, extended-release multilayer methylphenidate in adults with ADHD including 6-month open-label extension. J Attent Disor. 2021;25(10):1417-1428.
Monographie de CBiphentin®. Elvium Life Sciences. 15 avril 2024.
Monographie de CConcerta®. Janssen Inc. 25 août 2023.
Programme des médicaments d’ordonnance de Terre-Neuve-et-Labrador. Accessible au
https://nlpdp.bell.ca.
Date de consultation : 12 janvier 2024.
Wigal SB et coll. Reliability and validity of the SKAMP rating scale in a laboratory school setting. Psychopharmacol Bull. 1998;34(1):47-53.
Reiz JL et coll. Comparative bioavailability of single-dose methylphenidate from a multilayer-release bead formulation and an osmotic system: A two-way crossover study in healthy young adults. Clin Ther 2008;30(1):59-69.
